RMD
Resmed Inc Health Care Surgical & Medical Instruments & Apparatus S&P 500Russell 3000
$229.94Close
$33.2BMarket cap
$182.30 – $273.7252-week range
Late-januaryNext report · estimated
Highlights
Strengths
- Earnings growing EPS +23% year on year, faster than the quarter before (+21 pts)
Cautions
- Not in an uptrend 3 of 8 trend conditions
- Lagging the market RS 46 · weaker than 54% of stocks over 12 months
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
16%
1wk
down 9.1%
price change
1mo
up 4.0%
price change
12-month return
down 8%
market up 11% ·
its own down 19%
F-score
6 / 9
Mixed
Altman Z
11.21
Low risk
P/E
21.8×
price / earnings
PEG
2.25
P/E / EPS growth
P/B
5.0×
price / book
Earnings yield
up 5.9%
EBIT / enterprise value
Cheaper than
58%
of the market · around average
Revenue growth
up 10%
year on year
EPS growth
up 23%
latest quarter · +21 pts
Sales growth
up 6%
latest quarter · -3 pts
ROE
up 24%
return on equity
Free cash margin
up 29%
$1.6B FCF
D/E
0.06
long-term debt / equity
Net debt / EBITDA
-0.5×
net cash
Interest cover
—EBIT / interest
Piotroski tests
- profitability slipped from last year
- short-term liquidity weakened
- assets working less efficiently
- profitable on its assets
- generating cash from operations
- profits backed by cash
- reduced long-term debt
- no new shares issued
- gross margin widened
Repair signals
- Long-term debt down 39% ($0.7B → $0.4B)
- Gross margin 59.4% → 61.1%
Trade setup
ATR%
3.0%
$6.90 a day · 2×ATR $216.13
RS
46 / 99
vs the universe
Trend
3 / 8
trend template
Relative volume
2.8×
vs 50-day average
Up/down volume
0.96
50 sessions
Implied move
—
no scheduled report
Trend template · 3 of 8
- Price above the 150 and 200-day averages: passes
- 150-day average above the 200-day: fails
- 200-day average rising for a month: fails
- 50-day average above the 150 and 200-day: passes
- Price above the 50-day average: fails
- At least 30% above the 52-week low: fails
- Within 25% of the 52-week high: passes
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- No restatement or impairment
- Equity positive
- Interest covered
- No material dilution
- Profits tracking cash
- Margins and revenue not shrinking
Last reported
Oct 29, 2026
Results reaction
Oct 29, 2026-6% vs market2 sessions after results
Options
$538,90131.6% IV · activity
Financials
- Gross 61%
- Net 27%
- Free cash 29%
- Cash
- Long-term debt
| FY2021Jun 30, 2021 | FY2022Jun 30, 2022 | FY2023Jun 30, 2023 | FY2024Jun 30, 2024 | FY2025Jun 30, 2025 | FY2026Jun 30, 2026 | |
|---|---|---|---|---|---|---|
| Revenue | $3.2B | $3.6B | $4.2B | $4.7B | $5.1B | $5.7B |
| Gross margin | 58% | 57% | 56% | 57% | 59% | 61% |
| Operating income | $903.7M | $1.0B | $1.1B | $1.3B | $1.7B | $1.9B |
| Net income | $474.5M | $779.0M | $898.0M | $1.0B | $1.4B | $1.5B |
| Net margin | 15% | 22% | 21% | 22% | 27% | 27% |
| Earnings per share | $3.24 | $5.30 | $6.09 | $6.92 | $9.51 | $10.43 |
| Free cash flow | $634.0M | $216.3M | $573.6M | $1.3B | $1.7B | $1.6B |
| Free cash margin | 20% | 6% | 14% | 28% | 32% | 29% |
| Cash | $295.3M | $273.7M | $227.9M | $238.4M | $1.2B | $1.5B |
| Long-term debt | $643.4M | $765.3M | $1.4B | $697.3M | $658.4M | $399.4M |
| Shareholders' equity | $2.9B | $3.4B | $4.1B | $4.9B | $6.0B | $6.6B |
| Shares outstanding | 145.65m | 146.41m | 147.06m | 146.90m | 146.39m | 144.24m |
What options price now
- Expected 1-month range The at-the-money straddle for the expiry nearest a month out, as a share of the price: the move, either way, the option market is pricing by then. The range is the price plus and minus that move; the stock ends inside it a little more often than not. Methodology
- $215 – $244 ±6.3% by Nov 20, 2026
- Swings expected vs recent The daily swings the options are priced for (implied volatility) against the swings the stock actually had over the last 20 sessions (realised volatility). Bigger means options charge for more movement than the stock has been delivering; smaller, less. On a contract row, that contract's own implied volatility over the stock's realised. Methodology
- Smaller 31.6% priced · 41.6% recent
- Next month vs later At-the-money implied volatility for 8-45 day expiries over 46-90 day ones: whether options price the coming month as choppier or calmer than the two after it. Ahead of a report it usually reads choppier, and the extra comes out once the report is out. Methodology
- Choppier
- Crash protection What options that pay off in a fall cost against options that pay off in a rise (the 25-delta skew), compared with this company's own normal - the median of its stored nightly readings, once there are 20 - and with five sessions ago. Protection costs a little more than upside on most shares. More than usual means readers of the chain are paying up to insure against a drop; it does not say which way the stock will go. Methodology
- past week: costs less
Positioning
- Premium traded
- $538,901 calls $454,704 · puts $84,198 · latest session
- 0.19× +0.11 over the week
- Open interest added The change over five sessions in option positions left open overnight, calls and puts. A rise means positions were added. It cannot say whether they were bought or sold, so more calls is not a vote for a rise: a call is as often sold against shares already held. Methodology
- calls +369 · puts +2.52k past week
For options traders: ATM IV 31.6% (-6.3% 1w) · 1m ÷ 3m IV 1.09 · 25Δ skew -1.1 pts · Net GEX -$5.4M
Most traded contracts
No contract passed the liquidity filters this week.
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Oct 30, 2026 | Quarterly ↗ | Sep 30, 2026 | 30d |
| Aug 13, 2026 | Annual ↗ | Jun 30, 2026 | 44d |
| May 1, 2026 | Quarterly ↗ | Mar 31, 2026 | 31d |
| Jan 30, 2026 | Quarterly ↗ | Dec 31, 2025 | 30d |
| Oct 31, 2025 | Quarterly ↗ | Sep 30, 2025 | 31d |
| Aug 8, 2025 | Annual ↗ | Jun 30, 2025 | 39d |
| Apr 24, 2025 | Quarterly ↗ | Mar 31, 2025 | 24d |
| Jan 31, 2025 | Quarterly ↗ | Dec 31, 2024 | 31d |
| Oct 25, 2024 | Quarterly ↗ | Sep 30, 2024 | 25d |
| Aug 9, 2024 | Annual ↗ | Jun 30, 2024 | 40d |
| Apr 26, 2024 | Quarterly ↗ | Mar 31, 2024 | 26d |
| Jan 25, 2024 | Quarterly ↗ | Dec 31, 2023 | 25d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 29, 2026 | Results · Other events ↗ |
| Sep 1, 2026 | Other events ↗ |
| Aug 17, 2026 | Auditor change · Director or officer change · Regulation FD ↗ |
| Aug 6, 2026 | Results · Other events ↗ |
| Jul 7, 2026 | Results · Regulation FD ↗ |
| Apr 30, 2026 | Director or officer change ↗ |
| Apr 30, 2026 | Results · Other events ↗ |
| Jan 29, 2026 | Results · Other events ↗ |
| Nov 20, 2025 | Director or officer change · Shareholder vote ↗ |
| Oct 30, 2025 | Results · Other events ↗ |
| Aug 18, 2025 | Director or officer change ↗ |
| Aug 1, 2025 | Director or officer change ↗ |